MISSISSAUGA, ON, April 28, 2017 /CNW/ - AstraZeneca commends the Government of Ontario for delivering a balanced budget while also increasing funding in critical areas of health care, including a signature new pharmacare plan to improve drug coverage for children and youth aged 24 and under. A balanced budget is an important step towards delivering health services in a sustainable manner and providing timely access to new medicines for patients.
Innovative medicines are transforming the treatment of diseases – bringing about major leaps in life expectancy and quality of life in such areas as Alzheimer's, cardiovascular disease, diabetes, HIV/AIDs and oncology, while also benefitting the health system by helping to eliminate costly surgeries or hospitalization. Through this Budget, the Government of Ontario has expanded patient access to medicines and acknowledged the important role of innovative medicines in improving the quality of health care for Ontarians.
"At AstraZeneca, we push the boundaries of science to deliver life-changing medicines to patients." said Ed Dybka, President, AstraZeneca Canada. "Innovative medicines play an integral role in helping patients live longer, healthier lives. We are very pleased to see the Government of Ontario's commitment to expanding access to medicines for youth, and we are committed to partnering with the province to further improve timely access for Ontarians."
Based in Mississauga, AstraZeneca is proud to be one of Canada's top contributors to health sciences research and development, supporting world-class research right here in Ontario that will advance our scientific knowledge and the care of patients around the world. AstraZeneca in Canada was recently designated a Global Clinical Trial Delivery site and will play an integral role within our global organization leading more than 30 global clinical trials in oncology, immuno-oncology and respiratory, some involving more than 40 countries worldwide. Our Clinical Trial Delivery team has grown to more than 110 Canadian employees, more than doubling in size since 2013.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases, and Respiratory. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 720 employees across the country and our AstraZeneca Canada headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.
SOURCE AstraZeneca Canada Inc.
For further information: Carlo Mastrangelo, Director, Corporate Communications, AstraZeneca Canada Inc., 905 615-6865